When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Michael Banks, MD, announces the faculty of The Doctor’s Channel’s upcoming Cases in Thoracic Oncology series. Expert faculty Ross Camidge, MD, PhD, and Erin Schenk, MD, PhD, will…
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
Mark Ballow, MD, of the University of South Florida, and Jolan Walter, MD, PhD, of the University of South Florida and Johns Hopkins All Children’s Hospital, discuss COVID-19…
In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Michael Hochman, MD, MPH, invites brother Steven Hochman, MD, MPH, on the set of Healthy Skeptic, MD to discuss all things related to routine annual blood panels that…
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
At the first virtual Immunotherapy Patient Summit, Leena Gandhi, MD, PhD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the latest immunotherapy options for patients with lung cancer. Immunotherapy…
